Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Long-Term Impact Factor of Dr. Scabies in Overall Treatment Success Rate
  • USA - English


News provided by

Dr.Scabies Natural Relief

Oct 09, 2014, 03:00 ET

Share this article

Share toX

Share this article

Share toX

Scabies Infographic
Scabies Infographic

Say yes to Dr. Scabies® as the ultimate choice for scabies treatment

Post this

Niagara Falls, New York (PRWEB) October 09, 2014 -- Dr. Scabies® has helped its clients address a variety of challenges related to treatment and management of scabies, from high-level questions to very detailed, ever-evolving needs. Without knowledge, scabies can be very terrifying to the affected individual and the entire household. Improved understanding of the cause and development of scabies has aided Dr. Scabies® in the advancement of treating the susceptible populations. Dr. Scabies® knows that the role of the big player is to expand the reach, share knowledge and expertise and produce phenomenal results.

Taking into consideration the increased number of reported incidents of life-threatening drug effects and treatment failures, Dr. Scabies® successfully re-created the treatment approach for scabies in ways that pharmaceutical products cannot attain. In the first quarter of fiscal 2014, Dr. Scabies® contributed 8% of scabies treatment success to the global campaign for eradicating scabies. On the second quarter, Dr. Scabies® produced 12% contribution and to sustain the momentum and achieve higher success rate for third quarter, Dr. Scabies® launched a Risk-Free Trial Program with the goal of increasing the rate of positive treatment outcome.

Evidence-based decision making in Prevention and Control is currently what drives these products to produce massive results however, it still need to create a more significant impact on the success rate. According to World Health Organization (WHO), “Scabies globally affects more than 130 million people at any time. Rates of scabies occurrence vary in the recent literature from 0.3% to 46%. In the developed world, outbreaks in health institutions and vulnerable communities contribute to significant economic cost in national health services.” There were no full reports generated as to whether the cases are properly treated and data are effectively managed and used in targeting and using interventions.

The substantial number of reported cases is definitely alarming that is why Dr. Scabies® focused on scabies which has been listed as one of the “Neglected diseases” that are endemic among low-income population in developing countries in which cost-effective treatment do not exist and where large-scale use of safe and effective treatment is limited. These are the obvious challenges that need to be conquered: difficulty in conducting diagnosis, treatment and follow up due to financial constraints, poor understanding of the nature of disease, people affected often live in remote rural areas with limited access to diagnosis and treatment.

In a typical scabies outbreak, the community catalyzes the sequence of events – from transmission to propagation of scabies, and the people’s actions and behavior are major contributing factors of the disease. Scabies is closely associated with human inhabitance, and the way people manage their surroundings influences scabies mites breeding and transmission. In addition, the treatment-seeking behavior of people also plays a role in the transmission and incidence of disease in the community. Therefore, Dr. Scabies® help communities to improve their activities and behavior in relation to scabies control and self-protection through effective health education through phone, chat and email support.

In order for Dr. Scabies® to share these burden, the formulators constantly seek ways on how to get Dr. Scabies® products land in each household affected with scabies. In desolate places where resources are lacking or completely non-existent, it is of utmost importance to treat scabies in one shot as it can be financially-challenging and psychologically draining to experiment on treatment modalities that do not work. The Dr. Scabies® Risk-Free Trial program allows patients to try it with confidence and only harbor positive results. Primary management of affected individuals involves application of all three Dr. Scabies® products and it is mandatory to treat the household at the same time as the symptomatic individual.

It is true that scabies do not pose immediate threat but the isolation, suffering and impaired body perception it comes with it are definitely unwarranted. The following factors contribute hugely to successful control – involvement and motivation, education, close follow-up, and prompt treatment of new case. What Dr. Scabies® gives to scabies-afflicted individuals and families are not just mere relief and treatment but actually a new lease on life.

About Dr. Scabies®
Dr. Scabies® is an all-natural brand of products that have specific formulation to achieve optimum results while establishing high margin of safety among consumers regardless of age, gender and socio-economic status. Dr. Scabies® only uses plant-based and naturally-derived ingredients that have high-grade quality and compliant with Food and Drug Administration (FDA) and Homeopathic Pharmacopoeia of the United States (HPUS) compendium so it is safe for personal daily treatment and environment. Dr. Scabies® pride itself as consumer-friendly brand for its experience in managing and treating scabies, proven systems, and all out support in providing safe and sound treatment advice.

Paulina S., Dr.Scabies Natural Relief, http://www.drscabies.com, +1 8447222437, [email protected]

Modal title

Dr. Scabies®  - Treatment For Scabies
Dr. Scabies® - Treatment For Scabies
Dr. Scabies®  - Treatment For Scabies - Leaflet
View PDF
Dr. Scabies® - Treatment For Scabies - Leaflet
7 parasites skin disease in the world - scabies
7 parasites skin disease in the world - scabies
Dr. Scabies®  - Treatment For Scabies Dr. Scabies®  - Treatment For Scabies - Leaflet 7 parasites skin disease in the world - scabies

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.